Federal Circuit Breathes New Life into Methods Claiming Use of an Antibody Genus

The Federal Circuit’s decision in Teva Pharmaceuticals v. Eli Lilly & Co. (Appeal No. 24-1094) clarifies how Patent Act Section 112’s written description and enablement requirements apply to methods of using antibodies.... By: Morgan Lewis